These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 11737761)

  • 1. The use of anti-interleukin-2 receptor antibodies in pediatric liver transplantation.
    Kelly DA
    Pediatr Transplant; 2001 Dec; 5(6):386-9. PubMed ID: 11737761
    [No Abstract]   [Full Text] [Related]  

  • 2. Anti-interleukin-2 receptor antibodies: basiliximab and daclizumab.
    Pascual J; Marcén R; Ortuño J
    Nephrol Dial Transplant; 2001 Sep; 16(9):1756-60. PubMed ID: 11522853
    [No Abstract]   [Full Text] [Related]  

  • 3. The role of newer monoclonal antibodies in renal transplantation.
    Vincenti F
    Transplant Proc; 2001; 33(1-2):1000-1. PubMed ID: 11267163
    [No Abstract]   [Full Text] [Related]  

  • 4. Induction immunosuppression with interleukin-2 receptor antibodies (basiliximab and daclizumab) in renal transplant recipients.
    Nair MP; Nampoory MR; Johny KV; Costandi JN; Abdulhalim M; El-Reshaid W; Al-Muzairai I; Ninan VT; Samhan M; Al-Mousawi M
    Transplant Proc; 2001 Aug; 33(5):2767-9. PubMed ID: 11498153
    [No Abstract]   [Full Text] [Related]  

  • 5. Basiliximab versus daclizumab combined with triple immunosuppression in deceased donor renal transplantation: a prospective, randomized study.
    Kandus A; Arnol M; Omahen K; Oblak M; Vidan-Jeras B; Kmetec A; Bren AF
    Transplantation; 2010 Apr; 89(8):1022-7. PubMed ID: 20075788
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interleukin-2R antagonists in the prevention of acute rejection in living donor transplantation.
    Ivanovski N; Popov Z; Kolevski P; Cakalaroski K; Spasovski G; Sikole A; Paneva-Masin J
    Transplant Proc; 2001; 33(7-8):3203-4. PubMed ID: 11750374
    [No Abstract]   [Full Text] [Related]  

  • 7. Limited benefits of induction with monoclonal antibody to interleukin-2 receptor in combination with tacrolimus, mycophenolate mofetil, and steroids in simultaneous kidney-pancreas transplantation.
    Lo A; Stratta RJ; Alloway RR; Egidi MF; Shokouh-Amiri MH; Grewal HP; Gaber AO
    Transplant Proc; 2001; 33(1-2):1701-3. PubMed ID: 11267477
    [No Abstract]   [Full Text] [Related]  

  • 8. Daclizumab.
    Mottershead M; Neuberger J
    Expert Opin Biol Ther; 2007 Oct; 7(10):1583-96. PubMed ID: 17916050
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Daclizumab and basiliximab: monoclonal mouse-man antibodies with effective immunosuppression without side effects].
    ter Meulen CG; Hilbrands LB; van Riemsdijk-van Overbeeke IC; Hené RJ; Christiaans MH; Hoitsma AJ
    Ned Tijdschr Geneeskd; 2000 Dec; 144(50):2396-400. PubMed ID: 11145094
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of Basiliximab Versus Daclizumab in Kidney Transplantation: A Meta-Analysis.
    Sun ZJ; Du X; Su LL; Zhang XD; Wang W
    Transplant Proc; 2015 Oct; 47(8):2439-45. PubMed ID: 26518947
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-interleukin 2-receptor antibodies: a comparative study with polyclonal antibodies in kidney transplantation: preliminary results.
    Martins L; Henriques AC; Dias L; Sarmento AM; Pereira MC; Guimarães S
    Transplant Proc; 2000 Dec; 32(8):2623-5. PubMed ID: 11134730
    [No Abstract]   [Full Text] [Related]  

  • 12. Anti-interleukin-2 receptor antibodies for the prevention of rejection in pediatric renal transplant patients: current status.
    Swiatecka-Urban A
    Paediatr Drugs; 2003; 5(10):699-716. PubMed ID: 14510627
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liver transplant induction trial of daclizumab to spare calcineurin inhibition.
    Heffron TG; Smallwood GA; Pillen T; Davis L; Martinez E; Romero R; Stieber AC
    Transplant Proc; 2002 Aug; 34(5):1514-5. PubMed ID: 12176462
    [No Abstract]   [Full Text] [Related]  

  • 14. Anti-interleukin 2 receptor antibodies and mycophenolate mofetil for treatment of steroid-resistant rejection in adult liver transplantation.
    Orr DW; Portmann BC; Knisely AS; Stoll S; Rela M; Muiesan P; Bowles MJ; Heaton ND; O'Grady JG; Heneghan MA
    Transplant Proc; 2005 Dec; 37(10):4373-9. PubMed ID: 16387124
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunosuppressive [correction of immunosupressive] agents and their actions.
    First MR
    Transplant Proc; 2002 Aug; 34(5):1369-71. PubMed ID: 12176401
    [No Abstract]   [Full Text] [Related]  

  • 16. Clinical advances in therapies targeting the interleukin-2 receptor.
    Church AC
    QJM; 2003 Feb; 96(2):91-102. PubMed ID: 12589007
    [No Abstract]   [Full Text] [Related]  

  • 17. Acute rejection after liver transplantation despite intragraft coating by interleukin-2 receptor-alpha with basiliximab.
    Kwekkeboom J; Maas M; Rietveld JH; Zondervan PE; Bouma GJ; Tilanus HW; Metselaar HJ
    Transplant Proc; 2001; 33(1-2):1071-3. PubMed ID: 11267195
    [No Abstract]   [Full Text] [Related]  

  • 18. IL-2 antibody induction and the outcome of pediatric renal transplants.
    Garcia CD; Barros VR; Schneider L; Alves MD; Silveira CG; Garcia VD
    Transplant Proc; 2002 Nov; 34(7):2914-5. PubMed ID: 12431655
    [No Abstract]   [Full Text] [Related]  

  • 19. The interleukin-2 inhibitors and their role in low-toxicity regimens.
    Nashan B
    Transplant Proc; 1999 Dec; 31(8A):23S-26S. PubMed ID: 10616557
    [No Abstract]   [Full Text] [Related]  

  • 20. Basiliximab versus daclizumab combined with triple immunosuppression in deceased donor renal graft recipients.
    Grego K; Arnol M; Bren AF; Kmetec A; Tomaziĉ J; Kandus A
    Transplant Proc; 2007 Dec; 39(10):3093-7. PubMed ID: 18089329
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.